The proceeds will be used to expand the company’s domestic sales force and move forward with the global commercialization of Stretta therapy for gastroesophageal reflux disease.
Recent data backing the efficacy of Stretta therapy for GERD has also led to expanded insurance coverage.
More articles on gastroenterology:
5 gastroenterologists making the news
11 statistics on gastroenterology & payer relationships
3 ways gastroenterologists can demonstrate value
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
